Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks?

Group 1 - Moderna's stock experienced a significant increase following the release of its fourth-quarter report, which showed better-than-expected sales and reaffirmed a 10% sales growth guidance for 2026 [1][1][1] - The company did not provide clarity on its ability to reach breakeven by 2028, leaving investors uncertain about future profitability [1][1] - The FDA recently declined to review Moderna's experimental flu vaccine, citing insufficient study data, which represents a setback for the company [1][1][1] Group 2 - Despite the FDA's rejection of the flu vaccine, Moderna has achieved a relative strength rating over 90, indicating strong performance compared to peers [1][1] - The company is facing challenges as sales from COVID-19 vaccines decline, prompting cost-cutting measures [1][1][1] - The overall market sentiment appears mixed, with Moderna's stock fluctuating amid regulatory news and performance metrics [1][1]